CClinicalTrials.gg
CompletedNCT03390790Updated Jul 19, 2019

Lidocaine for Pain After Urodynamic Testing

A Phase 4 interventional study of Lidocaine gel 2% and Standard lubricant gel in Voiding Disorders, Overactive Bladder and Urinary Incontinence, sponsored by Atlantic Health System. Completed at 1 site in United States. Open to female participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-07-19.

Sponsored by Atlantic Health System · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
Female
01

Study summary

Urodynamic testing can be associated with mild discomfort, particularly at the time of insertion, repositioning, and removal of the bladder catheter (a tube inserted into the bladder via the urethra). Few studies have investigated ways to improve patient comfort during this procedure. In this study, the investigators want to see if applying external lidocaine (a numbing gel) prior to the procedure can help to minimize patient discomfort.

Read the detailed description

Urodynamic testing can be associated with mild discomfort, particularly at the time of insertion, repositioning, and removal of the bladder catheter (a tube inserted into the bladder via the urethra). Few studies have investigated ways to improve patient comfort during this procedure. In this study, the investigators want to see if applying lidocaine (a numbing gel) prior to the procedure can help to minimize patient discomfort.

Participation in this study will involve only 1 clinic visit (for urodynamic testing), plus 2 phone calls to ask participants about pain (1 at 4-6 hours after testing; and 1 at 24 hours after testing). Additionally, the investigators will record any adverse effects (such as an allergic reaction to the gel or new irritation/pain) that happen within 2 weeks after testing.

Participants will be randomly assigned to receive either lidocaine gel or placebo gel for their urodynamic testing. The placebo gel will be a standard lubricant gel, meaning that it contains no active drug. The assigned study regimen will be chosen by chance, like flipping a coin. Participants will have an equal (50/50) chance of being given either study regimen. Neither the participant nor the study doctor or nurse practitioner will know which study regimen the participant is getting. Additionally, a member of the study team will ask participants about their pain level before and after the testing. The rest of the urodynamic testing procedure will take place exactly as it would if the participant was not in this research study.

02

Conditions studied

  • Voiding Disorders
  • Overactive Bladder
  • Urinary Incontinence
03

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • All female patients between the ages of 40-80 undergoing urodynamic testing.

Exclusion criteria

Exclusion Criteria:

  • Urinary tract infection or symptoms of infection at time of procedure or within past 2 weeks
  • History of urinary retention
  • Known or suggested history of urethral syndrome or painful bladder syndrome
  • Prior anti-incontinence surgery
  • Prior pelvic surgery with placement of transvaginal mesh
  • Known urethral or bladder anomaly including urethral diverticulum or congenital anomalies of the bladder or urethra
  • History of genital herpes outbreak within the past 3 months
  • Defects in mucosal surfaces including periurethral or vaginal abrasions, ulcerations, or lacerations
  • Neurologic disease affecting urethral sensation
  • Chronic pelvic pain
  • Contraindication or allergy to topical anesthetic
  • Pregnancy
  • Syncopal episode during preparation for or execution of uroflowometry
04

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
134 participants (actual)

Study arms

  • Experimental
    Lidocaine gel

    If assigned to this arm, participants have lidocaine gel 2% applied to their external urethra and vagina one time prior to the urodynamics procedure.

    Drug: Lidocaine gel 2%

  • Placebo comparator
    Lubricant gel

    If assigned to this arm, participants will have a standard lubricant gel applied to their external urethra and vagina prior to the urodynamics procedure.

    Other: Standard lubricant gel

Interventions

  • DrugLidocaine gel 2%

    If assigned to this intervention via randomization, participants will receive lidocaine (numbing) gel prior to their urodynamics procedure.

  • OtherStandard lubricant gel

    If assigned to this intervention via randomization, participants will receive standard lubricant gel prior to their urodynamics procedure.

05

What researchers measure

Primary outcomes

  1. The change in patient visual analog pain score (vaginal area only) from before procedure to 4-6 hours after urodynamic testing

    Participants will rate their pain according to a visual analog pain scale from 0 (no pain) to 100 (worst pain imaginable).

    Time frame: Baseline and 4-6 hours post procedure.

Secondary outcomes

  1. Change in patient visual analog pain score (vaginal area only) from before procedure to 24 hours after urodynamic testing.

    Participants will rate their pain according to a visual analog pain scale from 0 (no pain) to 100 (worst pain imaginable).

    Time frame: Baseline and 24 hours post procedure.

  2. Patient visual analog pain score (vaginal area only) before procedure, at conclusion of all procedure-related activities, 4-6 hours after procedure, and 24 hours after procedure.

    Participants will rate their pain according to a visual analog pain scale from 0 (no pain) to 100 (worst pain imaginable).

    Time frame: Baseline and 24 hours post procedure.

  3. To assess voiding difficulties and other adverse events immediately after urodynamic testing, at 4-6 hours, 24 hours, and two weeks after urodynamic testing.

    Participants will receive a phone call at 4-6 hours and 24 hours after urodynamic testing. Any study participant-initiated complaints of voiding difficulties within two weeks of the procedure will be documented and addressed.

    Time frame: Baseline and 2 weeks post-procedure.

  4. Urodynamic findings

    Standard urodynamics findings will be analyzed.

    Time frame: At time of procedure.

  5. Procedure time

    Procedure time will be recorded for all subjects.

    Time frame: At time of procedure.

06

Study locations

1 site
  • Atlantic Health System
    Morristown, New Jersey 07960, United States
07

References and documents

Publications

  • Avondstondt AM, Chiu S, Salamon C. Periurethral Lidocaine Does Not Decrease Pain After Urodynamic Testing in Women: A Double-Blinded Randomized Control Trial. Female Pelvic Med Reconstr Surg. 2021 May 1;27(5):e528-e532. doi: 10.1097/SPV.0000000000000983. PubMed 33208652 ↗
08

Registry details

Key details

Study ID
NCT03390790
Lead sponsor
Atlantic Health System
Responsible party
charbel salamon (Principal Investigator, Atlantic Health System) — Principal investigator
First posted
Jan 4, 2018
Start date
Jan 25, 2018
Primary completion
Mar 29, 2019
Completion
Mar 29, 2019
Last update
Jul 19, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion